Monday, October 08, 2018 1:36:04 AM
I can't remember what caused me to look at Amarin, unlike the dates 10/16/2013 and 9/24/2018 that I remember quite well. Back in the day, I think the Apple iPhone stock app carried articles by Seeking Alpha and/or Motley Fool and that's likely where I noticed it. Took first position end of May 2013. Had just retired April 1 so I had some cash and time to amuse myself searching for investment ideas. Oh, and I opened our trading account with great anticipation in December 2007. So began my education in the school of investment hard knocks. Didn't sell though, stubborn that way.
By the ADCOM, I had 5,000 shares @~$7 so when it dropped to ~$2, I didn't panic and I generally don't sell unless it looks hopeless.
Not sure when I joined iHub but not right away. People kept mentioning iHub on yahoo and Stocktwits so I joined too. Anyway, the more I learned, the more I added, even at $0.80.
Being the curious type and my Dad dying of his 3rd heart attack at 67, I read everything that folks posted. Probably have a few hundred articles bookmarked. JL's asymmetrical bet notion and scientific perspective as well as HG, Zum, Sam, and others were influential . My wife and I started talking EPA 500 2-1/2 years ago and have experienced positive effects.
By the ADCOM, I had 5,000 shares @~$7 so when it dropped to ~$2, I didn't panic and I generally don't sell unless it looks hopeless.
Not sure when I joined iHub but not right away. People kept mentioning iHub on yahoo and Stocktwits so I joined too. Anyway, the more I learned, the more I added, even at $0.80.
Being the curious type and my Dad dying of his 3rd heart attack at 67, I read everything that folks posted. Probably have a few hundred articles bookmarked. JL's asymmetrical bet notion and scientific perspective as well as HG, Zum, Sam, and others were influential . My wife and I started talking EPA 500 2-1/2 years ago and have experienced positive effects.
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
